Cypin Production to Bring Together Top BioPharma Leaders in U.S. and China
Cypin Production Works to Build Bridges Between Emerging Markets.
- Philadelphia, PA-NJ (1888PressRelease) March 23, 2011 - Cypin Production, a newly established leader bringing together experts in biopharmaceuticals in the United States and China, is pleased to announce it will host U.S.-CHINA PHARMA™: Innovative Strategies and Partnership Models for R&D Success. The conference, taking place May 23-24, 2011, at the Hub Cira Centre in Philadelphia, will assemble hundreds of senior pharmaceutical and biotech managers from U.S. and China to discuss best practices in the industry.
"U.S.-CHINA PHARMA is the new industry meeting place for those who want to tap into the Chinese market and learn about China's fast-growing capabilities in biopharmaceutical R&D," said Dr. Evan Loh, Sr. Vice President at Pfizer. "We are excited to bring together leading experts for this the inaugural conference event."
Conference participants will network with practitioners of preclinical and clinical development from North America, China, and Europe, learn how to increase R&D productivity, debate product and globalization strategies, and uncover China's R&D capabilities and landscape. Participants also have the unique opportunity to meet face-to-face with hundreds of executives who are looking for R&D partnership opportunities throughout North America and China, all in one place.
U.S.-China Pharma, sponsored by Morrison & Foerster's Life Sciences Group; Orrick Herrington & Sutcliffe's China intellectual property group; and CRV Biotech Inc., will feature more than 30 C-Level speakers currently shaping collaborations between U.S. and China from some of the world's leading pharmaceutical companies, including Pfizer Worldwide Research & Development, Merck & Co., Novartis Vaccines & Diagnostics, Abbott Laboratories, Genzyme Transplant and Oncology, and more. (A complete list of conference speakers is available here.) Speakers and facilitators will explore key issues in building economic opportunities between these two markets.
According to Cypin Production, the organizer of the conference, the opportunity for synergy and growth provided by this conference is invaluable. "While major developed markets for biopharmaceuticals and life sciences will grow just 3 to 6 percent through 2014, emerging markets are expected to grow to between 14 and 17 percent," said conference event director Judy Tsui. "One of these especially vital and growing markets in biopharma is China."
For more information on U.S.-CHINA PHARMA, or to register for the conference, please visit http://www.chinarndpartnership.com/.
For media requests, more information on Cypin Production, or if you are interested in sponsoring, exhibiting, or speaking opportunities with Cypin, please contact Judy Tsui at 917-338-7778 or judy ( @ ) cypinproduction dot com dot
ABOUT CYPIN PRODUCTION
Cypin Production is a third-party organizer that brings together government officials, leading biopharma practitioners, and academics in both China and America to share insights, expertise and solutions to today's escalating challenges in this industry. The company name is inspired by Cypin, a protein discovered by Rutgers scientists in 2004 that regulates nerve cell and neuron branching in the brain, an important process in helping people learn. Cypin makes a different kind of connection: bringing together potential buyers and sellers at our targeted conferences in emerging pharmaceutical/life science areas by providing face-to-face business opportunities and practical industry solutions for industry leaders through conferences and meetings.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam